

## Synthesis and antibacterial activity of 1,3,4-oxadiazolyl-1,8-naphthyridines

K Mogilaiah\* & K Vidya

Department of Chemistry, Kakatiya University, Warangal 506 009, India

E-mail: mogilaiah\_k@yahoo.co.in

Received 12 August 2005; accepted (revised) 28 March 2006

Condensation of (2-oxo-3-phenyl-2*H*-[1,8]naphthyridin-1-yl)-acetic acid hydrazide **2** with different acetophenones yields the corresponding acetophenone (2-oxo-3-phenyl-2*H*-[1,8]naphthyridin-1-yl)methylcarbonyl hydrazones **3**, which on treatment with acetic anhydride affords the respective 1-(4-acetyl-5-aryl-5-methyl-[1,3,4]oxadiazol-2-ylmethyl)-3-phenyl-1*H*-[1,8]naphthyridin-2-ones **4**. The structures of the compounds **3** and **4** have been confirmed on the basis of analytical and spectral data. The compounds **4** have been screened for their antibacterial activity.

**Keywords:** 1,8-Naphthyridinyl acetic acid hydrazide, acetophenones, condensation, 1,8-naphthyridinyl methylcarbonyl hydrazones acetic anhydride, cyclization, 1,3,4-oxadiazolyl-1, 8-naphthyridines

**IPC Code:** Int. Cl.<sup>8</sup> C07D

1,3,4-Oxadiazoles constitute one of the most active class of compounds possessing diverse pharmacological and microbiological activity<sup>1-4</sup>. Literature survey reveals that various 1,8-naphthyridines have attracted considerable attention as they are also endowed with a wide range of biological activity<sup>5-8</sup>. In the light of these findings and in view of sustained interest in the synthesis of 1,8-naphthyridine derivatives<sup>9-13</sup>, the synthesis of some new 1,3,4-oxadiazoles incorporating the 1,8-naphthyridine moiety *via* methylene bridge has been undertaken in order to assess their antibacterial profile.

Ethyl (2-oxo-3-phenyl-2*H*-[1,8]naphthyridin-1-yl)-acetate **1**, obtained by the alkylation of 3-phenyl-1,8-naphthyridin-2(1*H*)-one with ethyl chloroacetate in DMF in the presence of anhydrous K<sub>2</sub>CO<sub>3</sub>, on hydrazinolysis with refluxing hydrazine hydrate furnished the desired synthon, (2-oxo-3-phenyl-2*H*-[1,8]naphthyridin-1-yl)acetic acid hydrazide **2** (Ref. 13). Compound **2** on condensation with different acetophenones in ethanol containing a catalytic amount of glacial acetic acid yielded the corresponding acetophenone (2-oxo-3-phenyl-2*H*-[1,8]naphthyridin-1-yl)methylcarbonylhydrazones **3** in excellent yields. Cyclization of **3** with an excess of acetic anhydride afforded 1-(4-acetyl-5-aryl-5-methyl-[1, 3, 4]oxadiazol-2-ylmethyl)-3-phenyl-1*H*-[1, 8]naphthyridin-2-ones **4** (Scheme I).

The structures of the compounds **3** and **4** were established by their elemental analyses and spectral (IR and <sup>1</sup>H NMR) data (Table I).

### Antibacterial activity


The antibacterial activity was assayed using filter paper disc method of Vincent and Vincent<sup>14</sup> by measuring the zone of inhibition in mm. All the title compounds **4** were screened *in vitro* for their antibacterial activity against the Gram-negative *Escherichia coli* and Gram-positive *Bacillus subtilis* at 250 and 500 µg/disc concentrations. Known antibiotic Gentamycin was used as standard. The results are summarized in Table II.

### Experimental Section

Melting points were determined on a Cintex melting point apparatus and are uncorrected. The homogeneity of the compounds was determined by TLC. IR spectra were recorded in KBr pellet on a Perkin-Elmer Spectrum BX series FT-IR spectrophotometer and <sup>1</sup>H NMR spectra on a Varian Gemini 200 MHz spectrometer using TMS as internal standard.

### General procedure for the preparation of acetophenone (2-oxo-3-phenyl-2*H*-[1,8]naphthyridin-1-yl)methyl-carbonyl hydrazone, 3a-h

A mixture of **2** (0.01 mole) and appropriate acetophenone (0.01 mole) in ethanol with a trace of

**Table I** – Physical and  $^1\text{H}$  NMR spectral characterization data of compounds **3a-h** and **4a-h**

Compd	Ar	m.p. °C	Yield (%)	Mol. formula (Mol. wt)	Found (%) Calcd			$^1\text{H}$ NMR ( $\text{CDCl}_3$ ) ( $\delta$ , ppm)
					C	H	N	
<b>3a</b>	$\text{C}_6\text{H}_5$	264	85	$\text{C}_{24}\text{H}_{20}\text{N}_4\text{O}_2$ (396)	72.98 (72.72)	5.09 5.05	14.20 14.14	2.22 (s, 3H, $\text{CH}_3$ ), 5.92 (s, 2H, $\text{CH}_2$ ), 7.80 (m, 2H, $\text{C}_4\text{-H}$ , $\text{C}_6\text{-H}$ ), 7.93 (m, 1H, $\text{C}_4\text{-H}$ ), 8.55 (m, 1H, $\text{C}_7\text{-H}$ ), 8.80 (s, 1H, CONH), 7.11-7.50 (m, 10H, Ar-H)
<b>3b</b>	$p\text{-CH}_3\text{C}_6\text{H}_4$	250	94	$\text{C}_{25}\text{H}_{22}\text{N}_4\text{O}_2$ (410)	73.35 (73.17)	5.31 5.36	13.73 13.65	2.20 (s, 3H, $\text{CH}_3$ ), 2.30 (s, 3H, $\text{N}=\text{C-CH}_3$ ), 5.85 (s, 2H, $\text{CH}_2$ ), 7.85 (m, 2H, $\text{C}_4\text{-H}$ , $\text{C}_6\text{-H}$ ), 8.00 (m, 1H, $\text{C}_5\text{-H}$ ), 8.63 (m, 1H, $\text{C}_7\text{-H}$ ), 9.02 (s, 1H, CONH), 7.02-7.48 (m, 9H, Ar-H)
<b>3c</b>	$p\text{-CH}_3\text{OC}_6\text{H}_4$	230	90	$\text{C}_{25}\text{H}_{22}\text{N}_4\text{O}_3$ (426)	70.60 (70.42)	5.20 5.16	13.22 13.14	2.28 (s, 3H, $\text{CH}_3$ ), 3.83 (s, 3H, $\text{OCH}_3$ ), 5.82 (s, 2H, $\text{CH}_2$ ), 7.78 (m, 2H, $\text{C}_4\text{-H}$ , $\text{C}_6\text{-H}$ ), 7.97 (m, 1H, $\text{C}_5\text{-H}$ ), 8.50 (m, 1H, $\text{C}_7\text{-H}$ ), 9.12 (s, 1H, CONH), 7.15-7.52 (m, 9H, Ar-H)
<b>3d</b>	$p\text{-ClC}_6\text{H}_4$	260	92	$\text{C}_{24}\text{H}_{19}\text{N}_4\text{O}_2\text{Cl}$ (430.5)	66.73 (66.90)	4.46 4.41	13.09 13.01	2.23 (s, 3H, $\text{CH}_3$ ), 5.85 (s, 2H, $\text{CH}_2$ ), 7.80 (m, 2H, $\text{C}_4\text{-H}$ , $\text{C}_6\text{-H}$ ), 7.95 (m, 1H, $\text{C}_5\text{-H}$ ), 8.52 (m, 1H, $\text{C}_7\text{-H}$ ), 9.05 (s, 1H, CONH), 7.05-7.50 (m, 9H, Ar-H)
<b>3e</b>	$p\text{-BrC}_6\text{H}_4$	210	89	$\text{C}_{24}\text{H}_{19}\text{N}_4\text{O}_2\text{Br}$ (474)	60.99 (60.76)	4.05 4.01	11.88 11.81	2.22 (s, 3H, $\text{CH}_3$ ), 5.90 (s, 2H, $\text{CH}_2$ ), 7.82 (m, 2H, $\text{C}_4\text{-H}$ , $\text{C}_6\text{-H}$ ), 7.89 (m, 1H, $\text{C}_5\text{-H}$ ), 8.56 (m, 1H, $\text{C}_7\text{-H}$ ), 9.00 (s, 1H, CONH), 7.12-7.47 (m, 9H, Ar-H)
<b>3f</b>	$m\text{-NO}_2\text{C}_6\text{H}_4$	205	88	$\text{C}_{24}\text{H}_{19}\text{N}_5\text{O}_4$ (441)	65.48 (65.31)	4.36 4.31	15.95 15.87	2.27 (s, 3H, $\text{CH}_3$ ), 5.93 (s, 2H, $\text{CH}_2$ ), 7.88 (m, 2H, $\text{C}_4\text{-H}$ , $\text{C}_6\text{-H}$ ), 8.12 (m, 1H, $\text{C}_5\text{-H}$ ), 8.70 (m, 1H, $\text{C}_7\text{-H}$ ), 9.12 (s, 1H, CONH), 7.15-7.49 (m, 9H, Ar-H)
<b>3g</b>	$p\text{-NO}_2\text{C}_6\text{H}_4$	200	90	$\text{C}_{24}\text{H}_{19}\text{N}_5\text{O}_4$ (441)	65.49 (65.31)	4.35 4.31	15.94 15.87	2.25 (s, 3H, $\text{CH}_3$ ), 5.94 (s, 2H, $\text{CH}_2$ ), 7.92 (m, 2H, $\text{C}_4\text{-H}$ , $\text{C}_6\text{-H}$ ), 8.20 (m, 1H, $\text{C}_5\text{-H}$ ), 8.87 (m, 1H, $\text{C}_7\text{-H}$ ), 9.20 (s, 1H, CONH), 7.12-7.47 (m, 9H, Ar-H)

(Contd)

**Table I** – Physical and <sup>1</sup>H NMR spectral characterization data of compounds **3a-h** and **4a-h**—*Contd*

Compd	Ar	m.p. °C	Yield (%)	Mol. formula (Mol. wt)	Found (%) Calcd			<sup>1</sup> H NMR (CDCl <sub>3</sub> ) (δ, ppm)
					C	H	N	
<b>3h</b>	β-Naphthyl	262	87	C <sub>28</sub> H <sub>22</sub> N <sub>4</sub> O <sub>2</sub> (446)	75.53 (75.34)	4.98 4.93	12.62 12.56)	2.23 (s, 3H, CH <sub>3</sub> ), 5.92 (s, 2H, CH <sub>2</sub> ), 7.82 (m, 2H, C <sub>4</sub> -H, C <sub>6</sub> -H), 7.90 (m, 1H, C <sub>5</sub> -H), 8.56 (m, 1H, C <sub>7</sub> -H), 8.85 (s, 1H, CONH), 7.08-7.51 (m, 12H, Ar-H)
<b>4a</b>	C <sub>6</sub> H <sub>5</sub>	>300	60	C <sub>26</sub> H <sub>22</sub> N <sub>4</sub> O <sub>3</sub> (438)	71.41 (71.23)	5.06 5.02	12.72 12.79)	2.20 (s, 3H, CH <sub>3</sub> ), 2.35 (s, 3H, COCH <sub>3</sub> ), 5.43 (s, 2H, CH <sub>2</sub> ), 7.69 (m, 2H, C <sub>4</sub> -H, C <sub>6</sub> -H), 7.96 (m, 1H, C <sub>5</sub> -H), 8.51 (m, 1H, C <sub>7</sub> -H), 7.16-7.57 (m, 10H, Ar-H)
<b>4b</b>	<i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	>300	70	C <sub>27</sub> H <sub>24</sub> N <sub>4</sub> O <sub>3</sub> (452)	71.87 (71.68)	5.35 5.31	12.47 12.39)	2.18 (s, 3H, CH <sub>3</sub> ), 2.22 (s, 3H, CH <sub>3</sub> ), 2.42 (s, 3H, COCH <sub>3</sub> ), 5.52 (s, 2H, CH <sub>2</sub> ), 7.76 (m, 2H, C <sub>4</sub> -H, C <sub>6</sub> -H), 7.93 (m, 1H, C <sub>5</sub> -H), 8.38 (m, 1H, C <sub>7</sub> -H), 7.08-7.52 (m, 9H, Ar-H)
<b>4c</b>	<i>p</i> -CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>	>300	64	C <sub>27</sub> H <sub>24</sub> N <sub>4</sub> O <sub>4</sub> (468)	69.39 (69.23)	5.18 5.13	11.91 11.97)	2.20 (s, 3H, CH <sub>3</sub> ), 2.38 (s, 3H, COCH <sub>3</sub> ), 3.85 (s, 3H, OCH <sub>3</sub> ), 5.48 (s, 2H, CH <sub>2</sub> ), 7.80 (m, 2H, C <sub>4</sub> -H, C <sub>6</sub> -H), 8.05 (m, 1H, C <sub>5</sub> -H), 8.56 (m, 1H, C <sub>7</sub> -H), 7.05-7.43 (m, 9H, Ar-H)
<b>4d</b>	<i>p</i> -ClC <sub>6</sub> H <sub>4</sub>	>300	68	C <sub>26</sub> H <sub>21</sub> N <sub>4</sub> O <sub>3</sub> Cl (472.5)	66.21 (66.03)	4.49 4.44	11.92 11.85)	2.18 (s, 3H, CH <sub>3</sub> ), 2.36 (s, 3H, COCH <sub>3</sub> ), 5.54 (s, 2H, CH <sub>2</sub> ), 7.76 (m, 2H, C <sub>4</sub> -H, C <sub>6</sub> -H), 7.98 (m, 1H, C <sub>5</sub> -H), 8.57 (m, 1H, C <sub>7</sub> -H), 7.08-7.53 (m, 9H, Ar-H)
<b>4e</b>	<i>p</i> -BrC <sub>6</sub> H <sub>4</sub>	>300	62	C <sub>26</sub> H <sub>21</sub> N <sub>4</sub> O <sub>3</sub> Br (516)	60.66 (60.47)	4.02 4.07	10.93 10.85)	2.16 (s, 3H, CH <sub>3</sub> ), 2.38 (s, 3H, COCH <sub>3</sub> ), 5.56 (s, 2H, CH <sub>2</sub> ), 7.79 (m, 2H, C <sub>4</sub> -H, C <sub>6</sub> -H), 8.15 (m, 1H, C <sub>7</sub> -H), 8.60 (m, 1H, C <sub>7</sub> -H), 7.10-7.49 (m, 9H, Ar-H)
<b>4f</b>	<i>m</i> -NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	>300	61	C <sub>26</sub> H <sub>21</sub> N <sub>5</sub> O <sub>5</sub> (483)	64.89 (64.60)	4.40 4.35	14.57 14.49)	2.18 (s, 3H, CH <sub>3</sub> ), 2.43 (s, 3H, COCH <sub>3</sub> ), 5.58 (s, 2H, CH <sub>2</sub> ), 7.83 (m, 2H, C <sub>4</sub> -H, C <sub>6</sub> -H), 8.23 (m, 1H, C <sub>5</sub> -H), 8.85 (m, 1H, C <sub>7</sub> -H), 7.10-7.47 (m, 9H, Ar-H)
<b>4g</b>	<i>p</i> -NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	>300	63	C <sub>26</sub> H <sub>21</sub> N <sub>5</sub> O <sub>5</sub> (483)	64.87 (64.60)	4.41 4.35	14.56 14.49)	2.17 (s, 3H, CH <sub>3</sub> ), 2.45 (s, 3H, COCH <sub>3</sub> ), 5.57 (s, 2H, CH <sub>2</sub> ), 7.86 (m, 2H, C <sub>4</sub> -H, C <sub>6</sub> -H), 8.36 (m, 1H, C <sub>5</sub> -H), 8.92 (m, 1H, C <sub>7</sub> -H), 7.15 – 7.54 (m, 9H, Ar-H)
<b>4h</b>	β-Naphthyl	>300	62	C <sub>30</sub> H <sub>24</sub> N <sub>4</sub> O <sub>3</sub> (488)	73.95 (73.77)	4.96 4.92	11.56 11.48)	2.19 (s, 3H, CH <sub>3</sub> ), 2.42 (s, 3H, COCH <sub>3</sub> ), 7.90 (m, 2H, C <sub>4</sub> -H, C <sub>6</sub> -H), 8.02 (m, 1H, C <sub>5</sub> -H), 8.65 (m, 1H, C <sub>7</sub> -H), 7.12-7.49 (m, 12H, Ar-H)

glacial acetic acid was refluxed for 2 h. The solid that separated out on cooling was filtered and purified by recrystallization from ethanol to afford **3a-h**. The characterization data of compounds **3a-h** are given in **Table I**.

#### General procedure for the preparation of 1-(4-acetyl-5-aryl-5-methyl-[1, 3, 4]oxadiazol-2-yl-methyl)-3-phenyl-1H-[1,8]naphthyridin-2-one, **4a-h**

A mixture of **3a** (0.01 mole) and an excess of acetic anhydride (15 mL) was refluxed for 3 h. The excessive acetic anhydride was distilled off and the residue was poured into ice-cold water. The solid that

**Table II** — Antibacterial screening results of compounds **4a-h**

Compd	Inhibition zone in mm			
	<i>E. coli</i> at		<i>B. subtilis</i> at	
	250 µg/ disc	500 µg/ disc	250 µg/ disc	500 µg/ disc
<b>4a</b>	2.0	3.5	1.5	2.5
<b>4b</b>	3.5	5.0	2.0	3.5
<b>4c</b>	2.5	4.0	1.0	2.0
<b>4d</b>	5.0	7.5	3.5	5.5
<b>4e</b>	3.0	4.0	1.5	3.0
<b>4f</b>	2.0	3.0	1.0	2.5
<b>4g</b>	3.0	4.5	2.5	4.0
<b>4h</b>	1.5	2.5	1.0	2.0
Gentamycin	12	22	8	15

separated was filtered, washed with water and purified by recrystallization from ethanol to afford **4a-h**. The characterization data of compounds **4a-h** are given in **Table I**.

### Acknowledgement

The authors are thankful to the Director, IICT, Hyderabad for providing  $^1\text{H}$  NMR spectral data.

### References

- 1 Ramalingam T, Deshmukh A A, Sattur P B, Sheth U K & Naik S R, *J Indian Chem Soc*, 58, **1981**, 269.
- 2 Kalsi R, Pande K & Barthwal J P, *Indian J Chem*, 27B, **1998**, 197.
- 3 Dubey A K & Sangwan N K, *Indian J Chem*, 33B, **1994**, 1043.
- 4 Hui X P, Chu C H, Zhang Z Y, Wang Q & Zhang Q, *Indian J Chem*, 41B, **2002**, 2176.
- 5 Gorecki D K J & Hawes E M, *J Med Chem*, 20, **1977**, 124.
- 6 Balin G B & Tan W L, *Aust J Chem*, 37, **1984**, 1065.
- 7 Kuroda T, Suzuki F, Tamura T, Ohmori K & Hosie H, *J Med Chem*, 35, **1992**, 1130.
- 8 Ferrarini M, Clendio M, Calderone U & Lovella G, *Eur J Med Chem*, 33, **1998**, 383.
- 9 Mogilaiah K, Chowdary D S & Rao R B, *Indian J Chem*, 40B, **2001**, 43.
- 10 Mogilaiah K, Babu H R & Reddy N V, *Synth Commun*, 32, **2002**, 2377.
- 11 Mogilaiah K & Reddy N V, *Synth Commun*, 33, **2003**, 1067.
- 12 Mogilaiah K & Rama Sudhakar G, *Indian J Chem*, 42B, **2003**, 636.
- 13 Mogilaiah K, Srinivas K & Rama Sudhakar G, *Indian J Chem*, 43B, **2004**, 2014.
- 14 Vincent J C & Vincent H W, *Proc Soc Exptl Biol Med*, 55, **1944**, 162.